Stereotactic body radiation therapy for nonresectable tumors of the pancreas.

BACKGROUND: Stereotactic body radiation therapy (SBRT) has emerged as a potential treatment option for local tumor control of primary malignancies of the pancreas. We report on our experience with SBRT in patients with pancreatic adenocarcinoma who were found not to be candidates for surgical resection. METHODS: The prospective database of the first 20 consecutive patients receiving SBRT for unresectable pancreatic adenocarcinomas and a neuroendocrine tumor under an IRB approved protocol was reviewed. Prior to SBRT, cylindrical solid gold fiducial markers were placed within or around the tumor endoscopically (n = 13), surgically (n = 4), or percutaneously under computerized tomography (CT)-guidance (n = 3) to allow for tracking of tumor during therapy. Mean radiation dose was 25 Gray (Gy) (range 22-30 Gy) delivered over 1-3 fractions. Chemotherapy was given to 68% of patients in various schedules/timing. RESULTS: Patients had a mean gross tumor volume of 57.2 cm(3) (range 10.1-118 cm(3)) before SBRT. The mean total gross tumor volume reduction at 3 and 6 mo after SBRT were 21% and 38%, respectively (P < 0.05). Median follow-up was 14.57 mo (range 5-23 mo). The overall rate of freedom from local progression at 6 and 12 mo were 88% and 65%. The probability of overall survival at 6 and 12 mo were 89% and 56%. No patient had a complication related to fiducial markers placement regardless of modality. The rate of radiation-induced adverse events was: grade 1-2 (11%) and grade 3 (16%). There were no grade 4/5 adverse events seen. CONCLUSION: Our preliminary results showed SBRT as a safe and likely effective local treatment modality for pancreatic primary malignancy with acceptable rate of adverse events.

Using intraoperative radiation therapy--a case study.

The introduction of a mobile linear accelerator in the OR has made intraoperative radiation therapy (IORT) more plausible. An IORT treatment can deliver a single high dose of radiation to a tumor or tumor bed after surgical resection or surgical exposure of high risk areas. This article details a case study in which IORT was used on a patient with sigmoid carcinoma and the procedure outcomes.

A novel use of endoscopic clips in the treatment planning for radiation therapy (XRT) of esophageal cancer.

GOAL: To determine if the placement of metal endoclips improves radiotherapy (XRT) planning for esophageal cancer. BACKGROUND: XRT is an important modality in the treatment and palliation of esophageal cancer. Accurate simulation of the radiation field ensures optimal therapy while limiting toxicity. STUDY: Patients with esophageal carcinoma underwent EGD and endoscopic mucosal clip placement at the proximal and distal margins of the tumor. At XRT simulation the radiation oncologist simulated the field based on barium study, CT scan, and endoscopy report. A second radiation oncologist then assessed the ease of identification of the clips/margins of the tumor, shift in the field isocenter, and change in the radiation field width and length because of the metal clips. RESULTS: Seven patients with cancer of the esophagus had endoscopic clips placed followed by XRT simulation. The clips could be identified in all 7 patients. Simulation with the use of clips caused a shift in the field isocenter with a mean longitudinal shift (y-axis) of 3.5 cm (range, 1-6 cm) and a mean lateral shift (x-axis) of 0.33 cm (range, 0-1 cm). CONCLUSIONS: Endoscopically placed mucosal metal clips can aid field simulation when planning radiation therapy in patients with esophageal cancer.